NASDAQ: MIRA - MIRA Pharmaceuticals, Inc. Common Stock

Yield per half year: +15.49%

Share chart MIRA Pharmaceuticals, Inc. Common Stock

Extended chart Simple chart
Financial Markets by TradingView

About

MIRA Pharmaceuticals, Inc. operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a patent pending oral ketamine analog under investigation to deliver ultra-rapid antidepressant effects for individuals battling treatment-resistant depression, major depressive disorder with suicidal ideation, and post-traumatic stress disorder.

More details
In addition, its oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia. The company was formerly known as MIRA1a Therapeutics, Inc. MIRA Pharmaceuticals, Inc. was incorporated in 2020 and is headquartered in Miami, Florida.
Add to compare list
Add to watchlist
Add to portfolio
Add to notification price

EBITDA -6.8E-5
EV/EBITDA -1.28
IPO date 2023-08-03
Industry Pharmaceuticals
P/BV 4.46
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://mirapharmaceuticals.com
Цена ао 1.15
Число акций ао 0.01857 млрд
Change price per day: -1.28% (1.17)
Change price per week: -0.431% (1.16)
Change price per month: -26.9% (1.58)
Change price per 3 month: +110.84% (0.5478)
Change price per half year: +15.49% (1.0001)
Change price per year: -75.74% (4.76)
Change price per year to date: -48.21% (2.23)
All parameters

Underestimation

Title Value Grade
P/S 0 0
P/BV 4.46 4
P/E 0 0
EV/EBITDA -1.75 0
Total: 3

Efficiency

Title Value Grade
ROA, % -242.93 0
ROE, % -273.92 0
Total: 0

Dividends

Title Value Grade
Div yield, % 0 0
DSI 0 0
Total: 0

Debt

Title Value Grade
Debt/EBITDA -0.000594 10
Total: 9.8

Growth impulse

Title Value Grade
Yield Revenue, % 0 0
Yield Ebitda, % 12438.31 10
Yield EPS, % 13930.14 10
Total: 8
More

Institutions Volume Share, %
Gts Securities LLC 37852 0.26
Praetorian Wealth Management, Inc. 27500 0.19
Northern Trust Corporation 20454 0.14
Virtu Financial LLC 14658 0.1
Sandy Spring Bank 10375 0.07
AE Wealth Management LLC 10000 0.07
Royal Bank of Canada 3500 0.02

Head Job title Payment Year of birth
Mr. Erez Aminov CEO & Chairman N/A 1978 (46 years)
Ms. Michelle Yanez M.B.A. CFO, Secretary & Treasurer N/A 1972 (52 years)
Dr. Itzchak Angel Ph.D. Chief Scientific Advisor N/A

Address: United States, Baltimore. MD, 855 North Wolfe Street - open in Google maps, open in Yandex maps
Website: https://mirapharmaceuticals.com